Clinical trials: Innate Immune Response
Immunity, Innate, Colorectal Cancer
Analysis of Natural Killer Cell Activity (NKA) in Whole Blood in High Risk Subjects Undergoing Colonoscopy
This study will measure the activity of natural killer (NK) cells using the in vitro diagnostic device NK Vue in high risk subjects (Quebec risk categories P2, P3 and P4) scheduled for colonoscopy.
- Trial name
- ANKA-HR (NCT03249727)
- Testing
- IVDD for NK cell activity in whole blood
- Where
- 3 sites in Canada
- Volunteers
- 396 people
- Sponsor
- ATGen Canada Inc
Innate Immunity
Immunity Modification of Full Term Infants According to the Type of Feeding and Mode of Delivery
This is a single-center, double-blind, randomized controlled trial, with parallel groups and reference group. The aim of the study was to investigate the immunity of infant born from caesarian section and fed with formula milk…
- Trial name
- NCT04256356
- Testing
- Feeding infants with formula milk with fermented matrix at dosage of 4.6 g per 100g of powder, Feeding infants with formula milk with fermented matrix at dosage of 6.9 g per 100g of powder, Feeding infants with standard formula milk
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Heinz Italia SpA
Cutaneous Melanoma, Mucosal Melanoma
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability.
- Conditions
- Cutaneous Melanoma, Mucosal Melanoma, Cutaneous Squamous Cell Carcinoma (CSCC), Merkel Cell Carcinoma of Skin
- Trial name
- NCT07600476
- Testing
- KUP-101A
- Where
- 3 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Kupando GmbH
HPV Infection
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV
Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients. 1.
- Trial name
- 9vHPV-BCG (NCT06959563)
- Testing
- 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
HIV-1 Infection
Phase I/IIa Dose-escalation Clinical Study of VAC-3S
The purpose of this trial is to evaluate the safety and immunogenicity of the therapeutic vaccine candidate VAC-3S in HIV-1 infected patients under AntiRetroviral Therapy (ART) with undetectable viral loads.
- Trial name
- NCT01549119
- Testing
- VAC-3S
- Where
- 2 sites in France
- Volunteers
- 33 people
- Sponsor
- InnaVirVax
Rectal Cancer
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of CEA positive rectal cancer patients. 1.
- Trial name
- CEA+RC-BCG (NCT02403505)
- Testing
- CEA protein antigen plus BCG Vaccine Mix for percutaneous use
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Immune Response
Study to Evaluate the Ability of Sublingual MV130 to Induce the Expression of Trained Immunity in Peripheral Blood Cells
A mechanistic clinical trial with the aim to evaluate whether MV130 can induce the expression of a particular immune response (trained immunity) in peripheral blood cells.
- Trial name
- NCT05208060
- Testing
- MV130
- Where
- Spain
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Inmunotek S.L.
Recurrent Wheezing, Wheezing Lower Respiratory Illness
A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing
This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheezing
- Trial name
- NCT05857930
- Testing
- OM-85
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 296 people
- Sponsor
- OM Pharma SA
Asthma
No Resistance After Long Term Treatment SERETIDE
This multi centre, double blind, comparator controlled, parallel group study is to determine whether asthma treatment with high doses of fluticasone propionate (FP) redirects a Th2/ eosinophil response towards a more treatment…
- Trial name
- NCT00456313
- Testing
- FLIXOTIDE and SERETIDE
- Where
- 2 sites in Netherlands
- Sponsor
- GlaxoSmithKline
Healthy Subject, Immunity
The Effect of the Consumption of 4 Botanical Extracts on Immunity in Healthy Adults (B-4-Immune)
This study will evaluate the capacity of botanical extracts to modulate immune mechanisms compared to a placebo group in healthy volunteers.
- Trial name
- B-4-Immune (NCT05117385)
- Testing
- Botanical extract
- Where
- France
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Givaudan France Naturals
Immunity, Innate, Prostatic Neoplasm
Measurement of Natural Killer Cell Activity in Whole Blood in Men Being Screened for Prostate Cancer With Biopsy
This study will look at measuring the activity of natural killer (NK) cells using the in vitro diagnostic device NK Vue in subjects being screened for prostate cancer using prostate biopsy.
- Trial name
- ANKA-PCA (NCT03242265)
- Testing
- IVDD for NK cell activity in whole blood
- Where
- Canada
- Volunteers
- 84 people
- Sponsor
- ATGen Canada Inc
Viral Infections
A Study of Intranasal LMN-1001 in Healthy Adults
The purpose of this study is to optimize the tolerability of LMN-1001 relative to its ability to activate the host immune response. LMN-1001 is an investigational dry powder containing recombinant interferon lambda (IFN-λ).
- Trial name
- NCT07852208
- Testing
- LMN-1001
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Lumen Bioscience, Inc.
Neoplasms, Pancreatic
First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
In an unbiased CRISPR screen, RIPK1 was identified as a top gene contributing to immunotherapy resistance. In addition, RIPK1 has been reported to drive pancreatic oncogenesis.
- Trial name
- NCT03681951
- Testing
- GSK3145095, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline